Pharma Expanse

Pharma Expanse (PE) is a business development company focused in two areas: CDMO Services and Pharma Pipeline Assets. Pharma Expanse (PE) is partnered with CDMOs across the supply chain to provide development and manufacturing services for Pharmaceutical and Biotechnology companies. PE currently serves as Business Development for multiple CDMOs, totaling 20 Manufacturing Sites in 7 Countries. Capabilities encompass Small Molecule Drug Substance (including HPAPI), Oral Solid Dosage (expertise in controlled release), Regulatory Starting Materials (RSMs), Medicinal Chemistry, and niche manufacturing technologies. It’s an innovative business model – very different than the broker/agent model. For Pharma pipeline assets, Pharma Expanse is also working with a clinical stage anti-infective and women’s health company that is developing first-in-class therapeutics with novel mechanisms of action to treat multidrug resistant pathogens. The lead compound is beginning Phase 1 clinical trials in March 2024. The drug has already received FDA Fast Track and QIDP designations.